Interview: Juan López-Belmonte, CEO, Laboratorios Rovi, Spain
Since PharmaBoardroom interviewed Juan López-Belmonte, CEO of Rovi, in 2008, the market has changed drastically.…
Laboratorios Rovi
Last updated: 16.06.2014
ROVI is a fully integrated Spanish specialty pharmaceutical company engaged in the research, development, in-licensing, manufacturing and marketing of small molecule and specialty biologic drugs.
The Company has a diversified portfolio of products that it markets in Spain through its specialized sales force, calling on specialist physicians, hospitals and pharmacies. ROVI’s portfolio of 30 principal marketed products is currently anchored by the internally-developed, second generation low molecular weight heparin, Bemiparin.
ROVI’s research and development pipeline is focused primarily on the expansion of applications, indications and alternative mechanisms of action for the heparin-derived products and other glycosaminoglycans and on the development of new controlled release mechanisms based on ISMTM technology, with the aim of obtaining new pharmaceutical products that enable the regular administration of formulations which are administered daily in chronic and prolonged treatments.
ROVI manufactures the active biological ingredient (Bemiparin) for its principal proprietary products and for injectable pharmaceutical products developed by its own in-house research team, and utilizes its state-of-the-art filling and packaging capabilities to provide a broad array of toll manufacturing services to leading international pharmaceutical companies, primarily in the area of pre-filled syringes. In addition, ROVI provides contract manufacturing and packaging services of solid oral pharmaceutical dosage forms, using the most enhanced technology, Roller Compaction.
Additional information about ROVI is available on the company’s website: www.rovi.es
LABORATORIOS FARMACÉUTICOS ROVI
| C/ Alfonso Gómez, 45 |
| 28037, Madrid |
| Tel: |
| Fax: (+34) 913 047 881 |
| e-mail: rovi@rovi.es |
Interviews
Related
Spain / Grifols looks to Egypt; New Leadership Generation at Almirall; Ferrer’s EIB Loan; Esteve’s European Expansion
The latest from Spanish pharma, including the wide swathe of COVID-19 syringes, vaccines, masks, and tests being…
Spain / Pharma News Roundup September 2020
A roundup of the latest news from Spanish pharma, including J&J’s COVID-19 vaccine trial, the latest…
COVID-19 / Spain’s PharmaMar to Begin Trials for Aplidin
PharmaMar, a Spanish firm, is beginning Phase II clinical trials for its anti-tumour drug Aplidin to treat…
Report / New Spain Pharma Report September 2019 Out Now
Building on the topics covered in our March 2019 report, the latest edition of Healthcare & Life Sciences…
Juan Carlos Moro Rodríguez – CEO Iberia Cluster, DB Schenker
Juan Carlos Moro Rodríguez, CEO for the Iberia Cluster with DB Schenker, discusses the company’s plans to expand…
Company Profile / Jazz Pharmaceuticals Spain: Playing to a Different Beat
Though still one of the younger and lesser-known outfits inhabiting the European drug development landscape,…
Specialising to Succeed in the Spanish Women’s Health Market
In what is a highly competitive and crowded women’s health field in Spain, smaller players are having to be…
Philanthropy / A Boost for Spain’s Out-of-Date Hospital Equipment
Many of the world’s mega-rich are increasingly active philanthropists in the healthcare arena and Spain is no…
Profile / Aspen Spain: Thriving on Change
The global acquisition of GSK’s thrombosis portfolio and subsequent purchase of AstraZeneca’s anaesthesia…
Profile / Isdin's Juan Naya: To Space & Back
Perhaps the only CEO of a dermo-cosmetics company with a PhD in astrophysics and space technology as well as three…
Catalonia: At the Forefront of Spanish Healthcare
The North-Eastern region of Catalonia is one of Spain’s most prosperous and has been allocating increasingly…
Rocco de Bernardis – Managing Director, Johnson & Johnson Medical…
Rocco De Bernardis, managing director for Johnson & Johnson Medical Devices in Spain offers his insights into…
